



## Enanta Pharmaceuticals to Present at the H.C. Wainwright 1st Annual NASH Investor Conference

March 27, 2017

### ***Presentation to be Webcast on April 3 at 4:00 pm ET***

WATERTOWN, Mass.--(BUSINESS WIRE)--Mar. 27, 2017-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 1<sup>st</sup> Annual NASH Investor Conference in New York on April 3 at 4:00 pm ET. Dr. Luly will present an overview of Enanta's wholly-owned research and development programs with a focus on EDP-305, Enanta's FXR agonist for non-alcoholic steatohepatitis (NASH).

A live webcast and replay of the presentation will be accessible by visiting the "Calendar of Events" section on the "Investors" page of Enanta's website at [www.enanta.com](http://www.enanta.com). The webcast replay will be available following the presentation and will be archived for approximately 30 days.

### **About Enanta**

Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Enanta's research and development efforts are currently focused on the following disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Enanta has discovered novel protease inhibitors for use against the hepatitis C virus (HCV). These protease inhibitors, developed through Enanta's collaboration with AbbVie, include paritaprevir, currently marketed in AbbVie's HCV regimens, and glecaprevir (ABT-493), Enanta's second protease inhibitor product, which AbbVie is developing as part of its investigational HCV regimen of glecaprevir/pibrentasvir (G/P) now in registration in the U.S., the E.U. and Japan. Royalties and any further milestone payments from this collaboration will provide funding for Enanta's earlier development programs, including its Phase 1 FXR agonist program for NASH/PBC, and its preclinical programs for HBV and RSV. Please visit [www.enanta.com](http://www.enanta.com) for more information on Enanta's programs and pipeline.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20170327005800/en/>

Source: Enanta Pharmaceuticals, Inc.

### **Investor Contact**

Enanta Pharmaceuticals, Inc.  
Carol Miceli, 617-607-0710  
[cmiceli@enanta.com](mailto:cmiceli@enanta.com)

or

### **Media Contact**

MacDougall Biomedical Communications  
Kari Watson, 781-235-3060  
[kwatson@macbiocom.com](mailto:kwatson@macbiocom.com)